EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Emerging Therapies in Metabolic Health: A Comprehensive Review of GLP‐1, GIP, and Glucagon Agonists

Mohammed Shareef Khan, Utkarsh Bhutani, Hariharan Venugopal, Anuj Kumar Saini, Venkat Ramana Naidu, Sivacharan Kollipara iD

Journal of Peptide Science · 2026

DOI: 10.1002/psc.70083 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Peptide Science, 2026. Verfasst von Mohammed Shareef Khan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Biopharmaceutics Group, Global Clinical Management, Dr. Reddy's Laboratories Ltd., Integrated Product Development Organization (IPDO), Hyderabad, Tel…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Glucagon-Like Peptide 1, Hypoglycemic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 109 Literaturangaben. Gefördert von: Dr. Reddy's Laboratories Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Incretin‐based therapies have become central to type 2 diabetes (T2D) management, offering benefits beyond glycemic control, including weight reduction, cardiovascular protection, and emerging roles in renal and neurological health. This review addresses the question: What are the recent advances in GLP‐1, GIP, and glucagon receptor agonists, and how do formulation strategies overcome biopharmaceutical challenges? We systematically analyzed late‐stage clinical trials and formulation approaches for peptide‐based therapies. The review focuses on therapeutic efficacy, structural and physicochemical properties influencing absorption, distribution, and metabolic stability, and strategies to mitigate degradation pathways such as enzymatic hydrolysis and peptide aggregation. Additionally, innovative delivery systems such as oral peptide formulations and long‐acting injectables demonstrate promise in addressing inherent challenges of peptide drug delivery. By integrating clinical outcomes with mechanistic and formulation insights, this review highlights the evolving landscape of incretin‐based therapies and underscores innovative solutions for peptide stabilization and delivery. These findings provide a forward‐looking perspective for clinicians, researchers, and pharmaceutical scientists engaged in T2D management and drug development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Gastric Inhibitory PolypeptideGlucagon-Like Peptide 1Hypoglycemic AgentsGlucagonHumansPeptidesAnimalsGlucagon-Like Peptide-1 Receptor AgonistsReceptors, GlucagonDrug Delivery Systems

Stichwörter der Autor:innen

clinical trialsdrug deliveryemerging technologiesmetabolic diseasepeptide stability

Substanzen

Gastric Inhibitory PolypeptideGlucagon-Like Peptide 1Hypoglycemic AgentsGlucagonPeptidesGlucagon-Like Peptide-1 Receptor AgonistsReceptors, Glucagon

Autor:innen und Institutionen

  • Biopharmaceutics Group, Global Clinical Management, Dr. Reddy's Laboratories Ltd., Integrated Product Development Organization (IPDO), Hyderabad, Telangana, India.
  • Product Selection and Ideation Group (BRaIN), Dr. Reddy's Laboratories Ltd., Integrated Product Development Organization (IPDO), Hyderabad, Telangana, India.

ORCID-Profile: Sivacharan Kollipara

Förderung

  • Dr. Reddy's Laboratories Ltd

Zitieren

APA

Khan, M. S., Bhutani, U., Venugopal, H., Saini, A. K., Naidu, V. R., & Kollipara, S. (2026). Emerging Therapies in Metabolic Health: A Comprehensive Review of GLP‐1, GIP, and Glucagon Agonists. Journal of Peptide Science. https://doi.org/10.1002/psc.70083

Vancouver

Khan MS, Bhutani U, Venugopal H, Saini AK, Naidu VR, Kollipara S. Emerging Therapies in Metabolic Health: A Comprehensive Review of GLP‐1, GIP, and Glucagon Agonists. Journal of Peptide Science. 2026. doi:10.1002/psc.70083

BibTeX
@article{Khan2026,
  author = {Khan, Mohammed Shareef and Bhutani, Utkarsh and Venugopal, Hariharan and Saini, Anuj Kumar and Naidu, Venkat Ramana and Kollipara, Sivacharan},
  title = {Emerging Therapies in Metabolic Health: A Comprehensive Review of GLP‐1, GIP, and Glucagon Agonists},
  journal = {Journal of Peptide Science},
  year = {2026},
  doi = {10.1002/psc.70083}
}
Kostenlos starten →